Abstract
It is often helpful to a manufacturer hoping to market a new drug to look at what FDA has required in the past. In the case of anti-arrhythmic agents, however, the past is not too helpful, as we have approved only one anti-arrhythmic agent (other than propranolol), disopyramide, in the last decade and that was in 1977, providing relatively little guidance to a manufacturer in 1980.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Podrid PJ, Schoenberger A, Lown B. Congestive heart failure caused by oral disopyramide. N Eng J Med. 1980; 302:614–617.
Ruskin JN, DiMarco JP, Garan H. Out of hospital cardiac arrest: electrophysiologic observations and selection of long-term anti-arrhythmic therapy. N Eng J Med. 1980; 303:607–613.
Lown B. Sudden cardiac death: the major challenge confronting contemporary cardiology. Am J Cardiol. 1979; 43:315–328.
Roden DM, Steel SB, Higgins SB, Mayol RF, Cammans RE, Oates JA, Woosley RL. Total suppression of ventricular arrhythmias by encainide: pharmacodinetic and electrocardiographic characteristics. N Engl J Med. 1980; 302:877–882.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Martinus Nijhojf Publishers bv, The Hague.
About this chapter
Cite this chapter
Temple, R. (1981). Proposed New Means of Evaluating Anti-Arrhythmic Drugs. In: Morganroth, J., Moore, E.N., Dreifus, L.S., Michelson, E.L. (eds) The Evaluation of New Antiarrhythmic Drugs. Developments in Cardiovascular Medicine, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8270-3_12
Download citation
DOI: https://doi.org/10.1007/978-94-009-8270-3_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-8272-7
Online ISBN: 978-94-009-8270-3
eBook Packages: Springer Book Archive